Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Sattler, Sebastian ^a   Forlini, Cynthia ^b,c   Racine, Éric ^b,c,d   Sauer, Carsten ^a  

^a BIELEFELD UNIVERSITY   (Germany)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; ARTICLE; AWARENESS; COGNITIVE ENHANCEMENT; CONTEXTUAL FACTOR; CONTROLLED STUDY; FEMALE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; MALE; MEDICAL PARAMETERS; OUTCOME ASSESSMENT; PEER PRESSURE; PERCEPTIVE DISCRIMINATION; PHYSICAL PHENOMENA; SOCIAL ASPECT; SOCIAL INTERACTION; SOCIAL NETWORK; STUDENT ATTITUDE; SUBSTANCE ABUSE; TASK PERFORMANCE;

ADULT; DRUG USERS; FEMALE; HUMANS; INTERPERSONAL RELATIONS; MALE; NOOTROPIC AGENTS; PEER GROUP; PERCEPTION; PERFORMANCE-ENHANCING SUBSTANCES; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; STUDENTS; SUBSTANCE-RELATED DISORDERS;

EID: 84881086329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071452     Document Type: Article

References (87)

1. Bostrom N, Sandberg A, (2009) Cognitive enhanchment: methods, ethics, regulatory challenges. Science and Engineering Ethics 15: 311-341.
2. Glannon W, (2008) Psychopharmacological enhancment. Neuroethics 1: 45-54.
3. Hall W, (2004) Feeling 'better than well'. EMBO Reports 5: 1105-1109.
4. Normann C, Berger M, (2008) Neuroenhancement: status quo and perspectives. European Archives of Psychiatry and Clinical Neuroscience 258: 110-114.
5. Outram SM, Racine E, (2011) Developing public health approaches to cognitive enhancement: an analysis of current reports. Public Health Ethics 41: 93-105.
6. Sahakian B, Morein-Zamir S, (2007) Professoŕs little helper. Nature 450: 1157-1159.
7. Franke AG, Christmann M, Bonertz C, Fellgiebel A, Huss M, et al. (2011) Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 44: 331-338.
8. Racine E, Forlini C, (2010) Cognitive Enhancement, Lifestyle Choice or Misuse of Prescription Drugs? Neuroethics 3: 1-4.
9. Mache S, Eickenhorst P, Vitzthum K, Klapp BF, Groneberg DA, (2012) Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences. Wiener Medizinische Wochenschrift 162: 262-271.
10. Middendorff E, Poskowsky J, Isserstedt W (2012) Formen der Stresskompensation und Leistungssteigerung bei Studierenden. Hannover: HIS Hochschul-Informations-System.
11. Sattler S, Wiegel C, (2013) Test anxiety and cognitive enhancement: the influence of students' worries on their use of performance-enhancing drugs. Substance Use & Misuse 48: 220-232.
12. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, et al. (2008) Towards responsible use of cognitive enhancing drugs by the healthy. Nature 456: 702-705.
13. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain. The Journal of the American Medical Association 301: 1148-1154.
14. Franke AG, Lieb K, Hildt E, (2012) What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. PLoS ONE 7: e40047.
15. Nehlig A (2010) Is caffeine a cognitive enhancer? Journal of Alzheimers Disease 20 (Suppl 1): 85-94.
16. Dietz P, Striegel H, Franke A, Lieb K, Simon P, et al. (2013) Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy 33: 44-50.
17. Castaldi S, Gelatti U, Orizio G, Hartung U, Moreno-Londono AM, et al. (2012) Use of Cognitive Enhancement Medication Among Northern Italian University Students. Journal of Addiction Medicine 6: 112-117.
18. Chatterjee A, (2006) The promise and predicament of cosmetic neurology. Journal of Medical Ethics 32: 110-113.
19. Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, et al. (2004) Neurocognitive enhancement: what can we do and what should we do? Nature Reviews Neuroscience 5: 421-425.
20. Lynch G, Palmer LC, Gall CM, (2011) The likelihood of cognitive enhancement. Pharmacology Biochemistry and Behavior 99: 116-129.
21. Repantis D, Laisney O, (2010) Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacological Research 61: 473-481.
22. Repantis D, Schlattmann P, Laisney O, Heuser I, (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacological Research 62: 187-206.
23. Repantis D, Schlattmann P, Lainsey O, Heuser I, (2008) Antidepressants for neuroenhancement in healthy individuals: a systematic review. Poiesis & Praxis 6: 139-174.
24. Tye KM, Tye LD, Cone JJ, Hekkelman EF, Janak PH, et al. (2010) Methylphenidate facilitates learning-induced amygdala plasticity. Nature Neuroscience 13: 475-481.
25. Husain M, Mehta MA, (2011) Cognitive enhancement by drugs in health and disease. Trends in Cognitive Sciences 15: 28-36.
26. Maher B, (2008) Poll results: look whós doping. Nature 452: 674-675.
27. Lucke JC, Bell S, Partridge BJ, Hall WD, (2010) Weak evidence for large claims contribute to the phantom debate. BioSocieties 5: 482-483.
28. Outram SM, (2010) The use of methylphenidate among students: the future of enhancement? Journal of Medical Ethics 36: 198-202.
29. Outram SM, (2012) Ethical considerations in the framing of the cognitive enhancement debate. Neuroethics 5: 173-184.
30. Racine E, Forlini C, (2009) Expectations regarding cognitive enhancement create substantial challenges. Journal of Medical Ethics 35: 469-470.
31. Schermer M, (2008) On the argument that enhancement is "cheating". Journal of Medical Ethics 34: 85-88.
32. Novak PS, Kroutil LA, Williams RL, van Brunt DL, (2007) The nonmedical use of prescription ADHD medications: results from a national Internet panel. Substance Abuse Treatment, Prevention, and Policy 2: 32.
33. Arria AM, Caldeira KM, Vincent BK, O'Grady KE, Wish ED, (2008) Perceived harmfulness predicts nonmedical use of prescription drugs among college students: interactions with sensation-seeking. Prevention Science 9: 191-201.
34. Weyandt LL, Janusis G, Wilson KG, Verdi G, Paquin G, et al. (2009) Nonmedical prescription stimulant use among a sample of college students: relationship with psychological variables. Journal of Attention Disorders 13: 284-296.
35. Herman-Stahl MA, Krebs CP, Kroutil LA, Heller DC, (2006) Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents. Journal of Adolescent Health 39: 374-380.
36. Franke AG, Bonertz C, Christmann M, Engeser S, Lieb K, (2012) Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: a pilot study. AJOB Primary Research 3: 48-57.
37. Duitsman DM, Colbry SL, (1995) Perceived risk and use as predictors of substance use among college students. Health Values 19: 44-52.
38. McCabe SE, Knight JR, Teter CJ, Wechsler H, (2005) Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 99: 96-106.
39. Rabiner DL, Anasopoulos DA, Costello EJ, Hoyle RH, McCabe SE, et al. (2009) Motives and perceived consequences of nonmedical ADHD medication use by college students. Journal of Attention Disorders 13: 259-270.
40. Bennett T (1986) A decision-making approach to opoid addiction. In: Cornish DB, Clarke RV, The reasoning criminal: Rational choice perspectives on offending. New York: Springer. 83-102.
41. Porter SR, Whitcomb M, Weitzer WH, (2004) Multiple surveys of students and survey fatigue. New Directions for Institutional Research 121: 63-73.
42. Stafford JE, (1966) Influence of preliminary contact on mail returns. Journal of Marketing Research 3: 410-411.
43. Göritz AS, (2006) Incentives in web surveys: methodological issues and a review. International Journal of Internet Science 1: 58-70.
44. Banjo OC, Nadler R, Reiner PB, (2010) Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS ONE 5: e14322.
45. Bergström LS, Lynöe N, (2008) Enhancing concentration, mood and memory in healthy individuals: an empirical study of attitudes among general practitioners and the general population. Scandinavian Journal of Public Health 36: 532-537.
46. Hotze TD, Shah K, Anderson EE, Wynia MK, (2011) "Doctor, would you prescribe a pill to help me?" A national survey of physicians on using medicine for human enhancement. The American Journal of Bioethics 11: 3-13.
47. Jasso G, (2006) Factorial survey methods for studying beliefs and judgments. Sociological Methods & Research 34: 334-423.
48. Sabini J, Monterosso J, (2005) Judgments of the fairness of using performance enhancing drugs. Ethics & Behavior 15: 81-94.
49. Wallander L, (2009) 25 years of factorial surveys in sociology: a review. Social Science Research 38: 505-520.
50. Alves WM, Rossi PH, (1978) Who should get what? Fairness judgments of the distribution of earnings. American Journal of Sociology 84: 541-564.
51. Beck M, Opp KD, (2001) Der faktorielle Survey und die Messung von Normen. Kölner Zeitschrift für Soziologie und Sozialpsychologie 53: 283-306.
52. Faia MA, (1980) The vagaries of the vignette world. A comment on Alves and Rossi. American Journal of Sociology 85: 951-954.
53. Rossi PH, Alves WM, (1980) Rejoinder to Faia. American Journal of Sociology 85: 954-955.
54. Finch J, (1987) The Vignette Technique in Survey Research. Sociology 21: 105-114.
55. Landry GL, (2003) Ephedrine use is risky business. Current Sports Medicine Reports 2: 1-2.
56. Turk MP, (1997) Ephedrine's deadly edge. US News & World Report 123: 79-80.
57. Lipman AG, (2004) The federal ban on ephedrine dietary supplements. an important event for pain practitioners and patients. Journal of Pain and Palliative Care Pharmacotherapy 18: 1-4.
58. Tinsley J, Watkins D, (1998) Over-the-counter stimulants: abuse and addiction. Mayo Clinic Proceedings 73: 977-982.
59. Sepkowitz K, (2013) Energy drinks and caffeine-related adverse effects. JAMA 309: 243-244.
60. Alexander CS, Becker HJ, (1978) The use of vignettes in survey research. Public Opinion Quarterly 42: 93-104.
61. Choong P, Ho S, McDonald RA, (2002) An examination of the effects of social desirability bias on business ethics: research results. International Journal of Management 19: 3-9.
62. Wason KD, Polonsky MJ, Hyman MR, (2002) Designing vignette studies in marketing. Australasian Marketing Journal 10: 41-58.
63. Hilbe J (2011) Negative binomial regression. Cambridge: Cambridge University Press.
64. Long JS, Freese J (2001) Regression models for categorical and limited dependent variables. Thousand Oaks, CA: Sage Publications.
65. Lucke JC, Bell S, Partridge BJ, Hall WD, (2011) Deflating the neuroenhancement bubble. AJOB Neuroscience 2: 38-43.
66. Larriviere D, Williams MA, Rizzo M, Bonnie RJ, (2009) Responding to requests from adult patients for neuroenhancements. guidance of the ethics, law and humanities committee. Neurology 73: 1406-1412.
67. Harris J (2007) Enhancing evolution: The ethical case for making people better. Princeton: Princeton University Press.
68. Partridge BJ, Bell SK, Lucke JC, Yeates S, Hall WD, (2011) Smart drugs "as common as coffee": media hype about neuroenhancement. PLoS ONE 6: e28416.
69. Forlini C, Racine E, (2009) Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics 10: 9.
70. Commission de l'éthique de la science et de la technologie (2009) Position statement on psychotropic drugs and expanded uses: an ethical perspective. Québec.
71. Rosenfield D, Hebert PC, Stanbrook MB, Flegel K, Macdonald NE, (2011) Time to address stimulant abuse on our campuses. Canadian Medical Association Journal 183: 1345.
72. Forlini C, Racine E, (2009) Autonomy and coercion in academic "cognitive enhancement" using methylphenidate: perspectives of a pragmatic study of key stakeholders. Neuroethics 2: 163-177.
73. Eaton ML, Illes J, (2007) Commercializing cognitive neurotechnology- the ethical terrain. Nature Biotechnology 25: 393-397.
74. Reyna VF, Farley F, (2006) Risk and rationality in adolescent decision making: implications for theory, practice, and public policy. Psychological Science in the Public Interest 7: 1-44.
75. Müller CP, Schumann G, (2011) To use or not to use: expanding the view on non-addictive psychoactive drug consumption and its implications. Behavioral and Brain Sciences 34: 328-347.
76. Sutherland EH, Cressey D (1966) Principles of criminology. Philadelphia: Lippincott.
77. Valente TW, Gallaher P, Mouttapa M, (2004) Using social network to understand and prevent substance use: a transdiciplinary perspective. Substance Use & Misuse 39: 1685-1712.
78. Racine E (2010) Pragmatic neuroethics: improving treatment and understanding of the mind-brain. Basic bioethics. Cambridge, MA: MIT Press.
79. Beck L, Ajzen I, (1991) Predicting dishonest actions using the theory of planned behavior. Journal of Research in Personality 25: 285-301.
80. Kroneberg C, Heintze I, Mehlkop G, (2010) The interplay of moral norms and instrumental incentives in crime causation. Criminology 48: 259-294.
81. Tittle CR, Antonaccio O, Botchkovar E, Kranidioti M, (2010) Expected utility, self-control, morality, and criminal probability. Social Science Research 39: 1029-1046.
82. Farah MJ, (2011) Overcorrecting the neuroenhancement discussion. Addiction 106: 1190.
83. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, et al. (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry 47: 21-31.
84. Lizzio A, Wilson K, Simons R, (2002) University students' perceptions of the learning environment and academic outcomes: implications for theory and practice. Studies in Higher Education 27: 27-52.
85. Trigwell K, (2002) Approaches to teaching design subjects: a quantitative analysis. Art, Design & Communication in Higher Education 1: 69-80.
86. Ong AD, Weiss DJ, (2000) The Impact of Anonymity on Responses to Sensitive Questions. Journal of Applied Social Psychology 30: 1691-1708.
87. Tourangeau R, Yan T, (2007) Sensitive questions in surveys. Psychological Bulletin 133: 859-883.